Aeon Biopharma Financials
This page shows Aeon Biopharma (AEON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aeon Biopharma's EBITDA was $73.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 251.1% from the prior year.
Aeon Biopharma reported $42.0M in net income in fiscal year 2024. This represents an increase of 179.9% from the prior year.
Aeon Biopharma earned $72.93 per diluted share (EPS) in fiscal year 2024. This represents an increase of 19292.1% from the prior year.
Aeon Biopharma held $13K in cash against $0 in long-term debt as of fiscal year 2024.
Aeon Biopharma had 555,511 shares outstanding in fiscal year 2024. This represents a decrease of 99.6% from the prior year.
Aeon Biopharma invested $14.2M in research and development in fiscal year 2024. This represents a decrease of 59.2% from the prior year.
AEON Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $597K-43.9% | $1.1M+29.0% | $825K | N/A | $972K-78.1% | $4.4M-22.6% | $5.7M | N/A |
| SG&A Expenses | $1.9M-40.7% | $3.3M+4.3% | $3.1M | N/A | $3.0M-8.3% | $3.3M-28.6% | $4.6M | N/A |
| Operating Income | -$2.5M+42.5% | -$4.3M-839.0% | -$462K | N/A | -$4.0M-102.6% | $153.5M+307.0% | -$74.2M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.5M+31.7% | -$6.6M-173.0% | $9.1M | N/A | -$6.2M-103.8% | $164.1M+239.1% | -$118.0M | N/A |
| EPS (Diluted) | $-0.39+35.0% | $-0.60-126.3% | $2.28 | N/A | $-11.24-103.7% | $304.00+233.4% | $-227.87 | N/A |
AEON Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.7M-25.1% | $11.7M-15.5% | $13.8M+339.2% | $3.1M-21.5% | $4.0M-30.2% | $5.7M+89.1% | $3.0M-55.7% | $6.8M |
| Current Assets | $7.4M-27.8% | $10.3M-16.7% | $12.3M+674.9% | $1.6M-32.9% | $2.4M-41.0% | $4.0M+60.9% | $2.5M-59.9% | $6.2M |
| Cash & Equivalents | $5.9M-29.8% | $8.4M-19.2% | $10.4M+80253.8% | $13K-97.6% | $537K-84.4% | $3.4M+120.9% | $1.6M-69.8% | $5.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $28.6M+4.0% | $27.5M+9.5% | $25.1M-20.8% | $31.7M-12.1% | $36.1M+7.2% | $33.7M-83.3% | $201.4M+26.0% | $159.9M |
| Current Liabilities | $8.2M-9.9% | $9.1M+5.7% | $8.6M-38.9% | $14.1M+31.9% | $10.7M+2.8% | $10.4M-34.6% | $16.0M+22.3% | $13.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$19.9M-25.4% | -$15.9M-40.0% | -$11.3M+60.4% | -$28.6M+11.0% | -$32.1M-14.8% | -$27.9M+85.9% | -$198.4M-29.6% | -$153.0M |
| Retained Earnings | -$433.7M-1.1% | -$429.1M-1.6% | -$422.5M+2.1% | -$431.6M+0.5% | -$433.7M-1.4% | -$427.5M+27.7% | -$591.6M-24.9% | -$473.6M |
AEON Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$7.9M | N/A | N/A | N/A | -$8.6M | N/A |
| Capital Expenditures | N/A | N/A | $4K | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$7.9M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | -$4K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $18.3M | N/A | N/A | N/A | $5.0M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AEON Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -52.0%+5.0pp | -57.0%-122.9pp | 65.9% | N/A | -154.1%-3016.2pp | 2862.1%+6754.5pp | -3892.4% | N/A |
| Current Ratio | 0.90-0.2 | 1.12-0.3 | 1.43+1.3 | 0.11-0.1 | 0.22-0.2 | 0.39+0.2 | 0.16-0.3 | 0.48 |
| Debt-to-Equity | -1.44+0.3 | -1.74+0.5 | -2.22-1.1 | -1.11+0.0 | -1.12+0.1 | -1.21-0.2 | -1.02+0.0 | -1.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$28.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.11), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Financial Health Signals
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Similar Companies
Frequently Asked Questions
Is Aeon Biopharma profitable?
Yes, Aeon Biopharma (AEON) reported a net income of $42.0M in fiscal year 2024.
What is Aeon Biopharma's earnings per share (EPS)?
Aeon Biopharma (AEON) reported diluted earnings per share of $72.93 for fiscal year 2024. This represents a 19292.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aeon Biopharma's EBITDA?
Aeon Biopharma (AEON) had EBITDA of $73.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aeon Biopharma's operating cash flow?
Aeon Biopharma (AEON) generated -$20.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aeon Biopharma's total assets?
Aeon Biopharma (AEON) had $3.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Aeon Biopharma spend on research and development?
Aeon Biopharma (AEON) invested $14.2M in research and development during fiscal year 2024.
How many shares does Aeon Biopharma have outstanding?
Aeon Biopharma (AEON) had 555,511 shares outstanding as of fiscal year 2024.
What is Aeon Biopharma's current ratio?
Aeon Biopharma (AEON) had a current ratio of 0.11 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Aeon Biopharma's debt-to-equity ratio?
Aeon Biopharma (AEON) had a debt-to-equity ratio of -1.11 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aeon Biopharma's return on assets (ROA)?
Aeon Biopharma (AEON) had a return on assets of 1336.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aeon Biopharma's cash runway?
Based on fiscal year 2024 data, Aeon Biopharma (AEON) had $13K in cash against an annual operating cash burn of $20.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aeon Biopharma's debt-to-equity ratio negative or unusual?
Aeon Biopharma (AEON) has negative shareholder equity of -$28.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aeon Biopharma's Piotroski F-Score?
Aeon Biopharma (AEON) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Aeon Biopharma's earnings high quality?
Aeon Biopharma (AEON) has an earnings quality ratio of -0.48x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.